Xenetic Biosciences (XBIO) Research & Development (2014 - 2026)
Xenetic Biosciences' (XBIO) quarterly Research & Development came in at $661443.0 in Q1 2026, down 24.75% YoY from $879029.0 in Q1 2025, and down 14.48% on a QoQ basis from $773416.0 in Q4 2025.
Xenetic Biosciences (XBIO) Research & Development (2014 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 13 years of Research & Development data on file, last reported at $661443.0 in Q1 2026.
- Quarterly Research & Development fell 24.75% year-over-year to $661443.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 11.64% YoY) and the FY2025 annual result came in at $3.1 million, down 6.78% from the prior year.
- Research & Development eased to $661443.0 in Q1 2026, from $773416.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $2.1 million in Q2 2022 to a low of $367985.0 in Q3 2024.
- A 5-year average of $898874.0 and a median of $903243.0 in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 296.05% — and 2024, when it slumped 63.94%.
- Tracing XBIO's Research & Development over 5 years: stood at $1.2 million in 2022, then decreased by 18.23% to $975628.0 in 2023, then advanced by 6.83% to $1.0 million in 2024, then slipped by 25.79% to $773416.0 in 2025, then slipped by 14.48% to $661443.0 in 2026.
- The last three Research & Development figures came in at $661443.0 (Q1 2026), $773416.0 (Q4 2025), and $756482.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Xenetic Biosciences | 7.59 Mn | 1.12 Mn | - | 552,013.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 552,013.00 |
| Mar 31, 2026 | 661,443.00 |
| Dec 31, 2025 | 773,416.00 |
| Sep 30, 2025 | 756,482.00 |
| Jun 30, 2025 | 656,557.00 |
| Mar 31, 2025 | 879,029.00 |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | 367,985.00 |
| Jun 30, 2024 | 933,771.00 |
| Mar 31, 2024 | 944,321.00 |
| Dec 31, 2023 | 975,628.00 |
| Sep 30, 2023 | 1.02 Mn |
| Jun 30, 2023 | 903,243.00 |
| Mar 31, 2023 | 595,276.00 |
| Dec 31, 2022 | 1.19 Mn |
| Sep 30, 2022 | 398,803.00 |
| Jun 30, 2022 | 2.08 Mn |
| Mar 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 1.23 Mn |
| Sep 30, 2021 | 780,153.00 |